Examples of using B细胞淋巴瘤 in Chinese and their translations into English
{-}
-
Political
-
Ecclesiastic
-
Programming
帮助诊断B细胞淋巴瘤;
当保健医生认为你“可以具有B细胞淋巴瘤;
When a doctor thinks that you may have a B-cell lymphoma;弥漫大B细胞淋巴瘤原发纵隔（胸腺）大B细胞淋巴瘤.
Diffuse large B cell lymphoma Mediastinal large 当保健医生认为你“可以具有B细胞淋巴瘤;
When a healthcare practitioner thinks that you may have a B-cell lymphoma;年夏天，乔安妮被诊断出患有大量B细胞淋巴瘤。
In the summer of 2009 Joanne was diagnosed with large B-cell lymphoma.Combinations with other parts of speech
Usage with nouns
约40%病例发展为弥漫大B细胞淋巴瘤。
One-third of cases are diffuse large B-cell lymphoma.对于弥漫性大B细胞淋巴瘤，缓解率相对较低，约为40％至50％，但仍然“十分显著”。
For diffuse large B-cell lymphoma, remission rates are lower, about 40 to 50 percent, which is still"pretty remarkable.".鉴于CD20在B细胞淋巴瘤中表达，该抗原可以作为用于“靶向”这样的淋巴瘤的候选物。
Given the expression of CD20 in B-cell lymphomas, this antigen can serve as a candidate for“targeting” of such CXCR4表达增强弥漫性大B细胞淋巴瘤的播散，降低患者生存率。
CXCR4 expression enhances diffuse large B-cell lymphoma dissemination and decreases patient survival.关于在美国非霍奇金淋巴瘤的85％B细胞淋巴瘤是，根据美国癌症协会（ACS）。
About 85% of non-Hodgkin 弥漫性大B细胞淋巴瘤在成人中比在儿童中更常见，并且在成人中比在儿童中表现不同。
Diffuse large B-cell lymphoma is more common in adults than in children, and behaves differently in adults than in children.YESCARTA：Yescarta专为治疗一种叫做“大B细胞淋巴瘤”的癌症而开发，于2017年被FDA批准，2018年被欧盟批准。
YESCARTA: Developed to treat a cancer called large B cell lymphoma, Yescarta was approved by the FDA in 2017 and in the E.U. in 2018.研究人员推测，NK细胞的转移是治疗B细胞淋巴瘤的一种可能策略。
Our results show that the transfer of NK B细胞淋巴瘤占所有非霍奇金淋巴瘤的85%，其中有30%的病人被诊断为弥漫大B细胞淋巴瘤。
B-cell lymphomas account for 85 percent of all non-Hodgkin 在儿童和青少年中，弥漫性大B细胞淋巴瘤通常以与Burkitt淋巴瘤治疗相同的方式进行治疗。
In children and adolescents, diffuse large B-cell lymphoma is usually treated in the same way that Burkitt 这些情况下，大部分（约85％）将是由于B细胞淋巴瘤;
The majority of these cases(about 85%) will be due to B-cell lymphomas;国内NHL最常见的类型是弥漫性大B细胞淋巴瘤（DLBCL），约占40-50%（西方国家约30-40%）。
The most common type ofNHL in China is diffuse large B-cell lymphoma(DLBCL), accounting for 40-50%(about 30-40% in Western countries).研究人员推测，NK细胞的转移是治疗B细胞淋巴瘤的一种可能策略。
The team surmise that the transfer of NK 亚当被诊断出患有B细胞淋巴瘤-血细胞肿瘤-在他去世前大约九个月.
Adam was diagnosed with B-cell lymphoma- blood cell tumours- around nine months ago.鉴于CD20在B细胞淋巴瘤中表达，该抗原可以作为用于“靶向”这样的淋巴瘤的候选物。
When the condition of expression of CD20 in b-cell lymphoma this antigen may serve as a candidate for"targeting" of such 正的测试结果不仅有助于确认B细胞淋巴瘤的诊断和点不到B细胞淋巴瘤的亚型特异性。
A positive testresult only helps to confirm a diagnosis of B-cell lymphoma and does not point to a specific subtype of B-cell lymphoma.它已被批准用于治疗两种类型的癌症：B细胞前体急性淋巴细胞白血病（ALL）和弥漫性大B细胞淋巴瘤。
It's been approved to treat two types of cancer: 在美国，60%的NHL病例都是侵袭性的NHL，最常见的亚型是弥漫性大B细胞淋巴瘤。
Sixty percent of all NHL cases in the United States are aggressive NHL,with the most common subtype being diffuse large B-cell lymphoma.在显微镜下，PMBL看起来与弥漫性大B细胞淋巴瘤和霍奇金淋巴瘤相似。
Under the microscope,PMBL looks similar to both diffuse large B-cell lymphoma and to Hodgkin 当时被称为弥漫性组织细胞淋巴瘤（现在称为弥漫性大B细胞淋巴瘤）的患者也用同样的方案进行治疗。
Patients with what was then calleddiffuse histiocytic lymphoma(now diffuse large B-cell lymphoma) were treated with the same programs as well.美国所有非霍奇金淋巴瘤病例中约60%是侵略性的，其中最常见的亚型是扩散性大型B细胞淋巴瘤（DLBCL）。
Sixty percent of all NHL cases in the United States are aggressive NHL,with the most common subtype being diffuse large B-cell lymphoma.这些数据支持我们继续评估CTL019在改善特定类型B细胞淋巴瘤患者结局方面的潜在作用。
These data support our ongoing efforts to determine the potential role 这有助于建立B细胞淋巴瘤或残留或复发evaluate-的诊断治疗疾病后。
This can help establish the diagnosis of a B-cell lymphoma or evaluate for residual or recurrent disease after treatment.
